Exome Asset Management LLC Raises Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Exome Asset Management LLC raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 167.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 211,000 shares of the company's stock after buying an additional 132,093 shares during the period. BridgeBio Pharma comprises about 3.6% of Exome Asset Management LLC's investment portfolio, making the stock its 3rd biggest holding. Exome Asset Management LLC owned 0.11% of BridgeBio Pharma worth $5,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Profund Advisors LLC increased its holdings in BridgeBio Pharma by 1.1% in the second quarter. Profund Advisors LLC now owns 51,029 shares of the company's stock worth $1,293,000 after buying an additional 555 shares during the last quarter. Bfsg LLC raised its holdings in shares of BridgeBio Pharma by 175.6% during the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company's stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of BridgeBio Pharma by 17.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock valued at $135,000 after purchasing an additional 801 shares during the last quarter. Amalgamated Bank boosted its holdings in BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company's stock worth $123,000 after purchasing an additional 962 shares in the last quarter. Finally, Diversified Trust Co increased its position in BridgeBio Pharma by 3.0% during the third quarter. Diversified Trust Co now owns 36,772 shares of the company's stock worth $936,000 after buying an additional 1,059 shares during the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,156 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the sale, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $2,101,116.78. This represents a 4.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 27,389 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $613,787.49. Following the transaction, the chief executive officer now owns 4,897,443 shares of the company's stock, valued at $109,751,697.63. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.66% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BBIO. HC Wainwright upped their price target on BridgeBio Pharma from $43.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday, November 25th. Scotiabank upped their target price on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a "sector outperform" rating in a research report on Monday, November 25th. Leerink Partners dropped their price target on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a research report on Thursday, October 17th. Oppenheimer assumed coverage on shares of BridgeBio Pharma in a research note on Thursday, October 3rd. They issued a "market perform" rating for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research note on Monday, September 16th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.69.

BridgeBio Pharma Price Performance

Shares of NASDAQ BBIO traded down $0.18 during mid-day trading on Friday, hitting $27.49. The company had a trading volume of 1,482,601 shares, compared to its average volume of 1,909,427. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $44.32. The firm has a market cap of $5.20 billion, a P/E ratio of -11.41 and a beta of 1.08. The business's 50-day simple moving average is $25.58 and its 200-day simple moving average is $26.11.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.